52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Hikma Announces Agreement With Chiesi Group
Hikma, Arecor To Develop New, Ready-To-Use Injectable Medicine In US
Hikma Pharmaceutical Says Completed FDA Response For Generic Advair
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.
1 New Burlington Place
Said Samih Darwazah
Executive Chairman of the Board
Chief Executive Officer
Mazen Samih Talib Darwazah
Executive Vice Chairman of the Board, President of MENA
Chief Financial Officer
President, US Generics Division
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
London-listed drugmaker Hikma <HIK.L> improved annual revenue forecasts for its generic and injectables businesses on Friday as its boss looks to transform the company into a specialty pharma business.
London's FTSE 100 slipped on Friday after a report that the United States was delaying a decision on letting its companies do business with Huawei, casting a shadow over global markets, though WPP soared after a quarterly update.
Hikma Pharmaceuticals Plc raised its full-year revenue forecasts for its generic drug business on Friday and said sales in its injectables unit would be near the high end of its previous outlook range due to higher demand for its medicines.
Hikma Pharmaceuticals Plc on Friday backed its forecast for the full year, boosted by higher demand for its new drugs and generic medicines.
Hikma Pharmaceuticals Plc on Friday backed its forecast for the full-year, boosted by higher demand for its injectable drugs and a rebound in its generics business.
Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent jump in full-year core operating profit.
Hikma Pharmaceuticals Plc on Wednesday reported a 19 percent rise in full-year core operating profit, helped by strong demand for its injectable drugs and a rebound in its generics business.
London-listed pharmaceutical group Hikma <HIK.L> said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.
GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.
* HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS
Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.
Hikma Pharmaceuticals Plc named former Teva Pharmaceutical executive Sigurdur Olafsson as its CEO, as the Jordan-based drugmaker looks to improve its struggling generics business.
* SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR
Drugmaker Hikma Pharmaceuticals Plc said on Tuesday it appointed Sigurdur Olafsson as its chief executive, effective immediately.
Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.
* REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA
* VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)
* HIKMA PHARMACEUTICALS PLC - INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING Source text for Eikon: Further company coverage:
* HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM
Hikma Pharmaceuticals Plc <HIK.L> is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's <GSK.L> popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.